Stay updated on Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Sign up to get notified when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.

Latest updates to the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check77 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a clinical study on Hepatitis C, including details about the study's purpose, inclusion and exclusion criteria, and the previous version number. The new version introduces a new revision number and mentions Hepatitis C, but lacks the detailed information previously provided.SummaryDifference11%
- Check84 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.